Literature DB >> 11866437

Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose.

Ryuji Ikeda1, Tatsuhiko Furukawa, Masaki Kitazono, Kenji Ishitsuka, Hiroshi Okumura, Ayako Tani, Tomoyuki Sumizawa, Misako Haraguchi, Masaharu Komatsu, Hiroshi Uchimiya, Xiao-Qin Ren, Toshiro Motoya, Katsushi Yamada, Shin-ichi Akiyama.   

Abstract

An angiogenic factor, platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP), stimulates the chemotaxis of endothelial cells and confers resistance to apoptosis induced by hypoxia. 2-deoxy-D-ribose, a degradation product of thymidine generated by TP enzymatic activity partially prevented hypoxia-induced apoptosis. 2-Deoxy-D-ribose inhibits a number of components of the caspase-mediated hypoxia-induced apoptotic pathway. It inhibits hypoxia-induced caspase 3 activation, mitochondrial cytochrome c release, downregulation of Bcl-2 and Bcl-x(L), upregulation of hypoxia-inducible factor (HIF)-1 alpha, and loss of mitochondrial transmembrane potential in human leukemia HL-60 cell line. These findings suggest a molecular mechanism by which 2-deoxy-d-ribose confers the resistance to apoptosis. Thus 2-deoxy-D-ribose-modulated suppression of HIF-1 alpha expression could prevent the hypoxia-induced decrease of the anti-apoptotic Bcl-2 and Bcl-x(L) on the mitochondria. 2-Deoxy-L-ribose and its analogs may enhance apoptosis and suppress the growth of tumors by competitively inhibiting the activities of 2-deoxy-d-ribose and thus these analogs show promise for anti-tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866437     DOI: 10.1006/bbrc.2002.6432

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.

Authors:  Michael A Sheard; Matthew V Ghent; Daniel J Cabral; Joanne C Lee; Vazgen Khankaldyyan; Lingyun Ji; Samuel Q Wu; Min H Kang; Richard Sposto; Shahab Asgharzadeh; C Patrick Reynolds
Journal:  Exp Cell Res       Date:  2015-04-03       Impact factor: 3.905

2.  Structural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug design.

Authors:  Kamel El Omari; Annelies Bronckaers; Sandra Liekens; Maria-Jésus Pérez-Pérez; Jan Balzarini; David K Stammers
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

Review 3.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

4.  Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma.

Authors:  Donald S Backos; Kristofer S Fritz; Debbie G McArthur; Jadwiga K Kepa; Andrew M Donson; Dennis R Petersen; Nicholas K Foreman; Christopher C Franklin; Philip Reigan
Journal:  Neurochem Res       Date:  2013-06-07       Impact factor: 3.996

Review 5.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

6.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

Review 7.  Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Curr Drug Targets       Date:  2006-03       Impact factor: 3.465

Review 8.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

9.  Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.

Authors:  N S Brown; E H Streeter; A Jones; A L Harris; R Bicknell
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

10.  Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.

Authors:  Yoshinari Shinsato; Tatsuhiko Furukawa; Shunji Yunoue; Hajime Yonezawa; Kentarou Minami; Yukihiko Nishizawa; Ryuji Ikeda; Kohichi Kawahara; Masatatsu Yamamoto; Hirofumi Hirano; Hiroshi Tokimura; Kazunori Arita
Journal:  Oncotarget       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.